Clinical

Articles

In the advanced treatment setting, an FDA decision has indicated that the combination of pembrolizumab and lenvatinib may soon be available for certain patients with endometrial tumors and renal cell carcinoma. 

Pembrolizumab Plus Lenvatinib Earns Priority Review in 2 Disease Indications

Videos

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about her thoughts on the effect of the conference content across multidisciplinary specialties.

Ronnie Shapira-Frommer, MD, Discusses Multidisciplinary Care to Treat Gynecologic Malignancies 

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Next Steps for Exploring Pembrolizumab Monotherapy in Patients With Vulvar Squamous Cell Carcinoma 

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about patients with vulvar cancer who were responders to pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Characteristics of Responders With Vulvar Squamous Cell Carcinoma Treated on the KEYNOTE-158 Trial 

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on Results From the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

CancerNetwork® spoke with Ronnie Shapira-Frommer, MD, during the Society of Gynecological Oncology 2021 Virtual Annual Meeting on Women’s Cancer about data focusing on a cohort of patients with vulvar cancer treated with pembrolizumab monotherapy.

Ronnie Shapira-Frommer, MD, on the Rationale for the KEYNOTE-158 Trial in Patients With Vulvar Squamous Cell Carcinoma

Patients with heavily pretreated vulvar squamous cell carcinoma experienced responses with pembrolizumab monotherapy in a nonrandomized phase 2 trial, regardless of PD-L1 status. 


Pembrolizumab Induces Notable Response Rate in Patients With Pretreated Vulvar Squamous Cell Carcinoma

CancerNetwork® discussed updates in the treatment of gynecologic cancers with Ursula A. Matulonis, MD.

Ursula A. Matulonis, MD, on Various Advancements in Gynecologic Cancers Presented at SGO 2021

A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.

PRIMA Trial Finds QoL Not Reduced Despite Toxicities Observed in Patients with Gynecologic Malignancies

A study of patients with gynecologic cancer and COVID-19 found that neither having cancer nor receiving treatment for it worsened COVID-19 outcomes.

Gynecologic cancer | Topics